Baird Medical Investment (BDMD) Competitors

Baird Medical Investment (NASDAQ:BDMD) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.

Does the MarketBeat Community favor BDMD or STIM?

Neuronetics received 129 more outperform votes than Baird Medical Investment when rated by MarketBeat users.

Company	Underperform	Outperform
Baird Medical Investment	N/A	N/A
Neuronetics	Outperform Votes 129 68.62%	Underperform Votes 59 31.38%

Which has preferable earnings & valuation, BDMD or STIM?

Baird Medical Investment has higher earnings, but lower revenue than Neuronetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baird Medical Investment	$33.05M	1.18	N/A	N/A	N/A
Neuronetics	$74.89M	1.77	-$30.19M	-$1.37	-3.19

Is BDMD or STIM more profitable?

Baird Medical Investment has a net margin of 0.00% compared to Neuronetics' net margin of -50.09%. Baird Medical Investment's return on equity of 0.00% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baird Medical Investment	N/A	N/A	N/A
Neuronetics	-50.09%	-141.24%	-32.77%

Does the media favor BDMD or STIM?

In the previous week, Baird Medical Investment had 1 more articles in the media than Neuronetics. MarketBeat recorded 4 mentions for Baird Medical Investment and 3 mentions for Neuronetics. Neuronetics' average media sentiment score of 0.98 beat Baird Medical Investment's score of 0.64 indicating that Neuronetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baird Medical Investment	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neuronetics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer BDMD or STIM?

Neuronetics has a consensus price target of $5.50, suggesting a potential upside of 25.86%. Given Neuronetics' stronger consensus rating and higher possible upside, analysts clearly believe Neuronetics is more favorable than Baird Medical Investment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baird Medical Investment	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Neuronetics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Which has more risk and volatility, BDMD or STIM?

Baird Medical Investment has a beta of -0.58, meaning that its stock price is 158% less volatile than the S&P 500. Comparatively, Neuronetics has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500.

Do insiders and institutionals have more ownership in BDMD or STIM?

19.8% of Baird Medical Investment shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 78.9% of Baird Medical Investment shares are owned by insiders. Comparatively, 9.8% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Neuronetics beats Baird Medical Investment on 9 of the 14 factors compared between the two stocks.